Hang Yu

Hang Yu

Auto-generated profile, based on publicly available information

Hang Yu

Department of Basic Medicine, Harbin Medical University, Daqing, PR China (H. Yu)

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 May 2021 in Arteriosclerosis, Thrombosis, and Vascular Biology
Verified
Journal Article
Open access
PDF file
YJYuan Jiang
Yuan Jiang
HLHuiyu Liu
Huiyu Liu
HYHang Yu
Hang Yu
YZYang Zhou
Yang Zhou
JZJunting Zhang
Junting Zhang
DZDaling Zhu
Daling Zhu
Objective: Circular RNAs are emerging as important regulators of pulmonary hypertension where pyroptosis plays a critical role. However, whether and how the circular RNAs regulate pyroptosis remained unexplored. Here, we show evidence for the involvement of a specific circular RNA known as circ-Calm4 in pulmonary hypertension and the underlying signaling pathway in pyroptosis. Approach and Results: Circ-Calm4 was upregulated in both mouse model of pulmonary hypertension in vivo and cultured smooth muscle cells in vitro. We performed immunoblotting, quantitative real-time PCR, LDH (lactate dehydrogenase) release assay, Annexin V-FITC/propidium iodide double staining, Hoechst 33342/propidium iodide fluorescence staining, and immunostaining to clarify the roles of circ-Calm4 in pulmonary arterial smooth muscle cell pyroptosis. Silencing the circ-Calm4 with its small-interfering RNA mitigated the upregulation of pyroptosis related phenotypes induced by hypoxia. Luciferase reporter assays confirmed that miR-124-3p suppressed the luciferase activity of the circ-Calm4 and RNA fluorescence in situ hybridization showed the colocalization of circ-Calm4 and miR-124-3p. The circ-Calm4 was found to act as a competitive endogenous RNA to regulate miR-124-3p. The pyroptosis-related alterations were all diminished with miR-124-3p in hypoxic pulmonary arterial smooth muscle cells. Inhibition of the gene targeted by miR-124-3p encoding the Pdcd6 (programmed cell death protein 6) abrogated pyroptosis-related phenotypes under hypoxia stimulation. Conclusions: Our findings show a new signaling pathway, the circ-Calm4/miR-124-3p/ Pdcd6 axis was demonstrated in regulation of hypoxia-induced pyroptosis, which may potentially be useful for the design of therapeutic strategies for protecting the cellular functionality against pyroptosis as well as pulmonary hypertension.

24 August 2024 in European Journal of Pharmacology
Verified
Journal Article
Closed access
ALAijing Liu
Aijing Liu
YWYingqi Wang
Yingqi Wang
SZShuang Zheng
Shuang Zheng
ZBZhitu Bao
Zhitu Bao
HZHe Zhu
He Zhu
HYHang Yu
Hang Yu

1 October 2025 in Hypertension
Verified
Journal Article
Closed access
YWYingqi Wang
Yingqi Wang
LYLulu Yin
Lulu Yin
SZShuang Zheng
Shuang Zheng
ALAijing Liu
Aijing Liu
CLChunmiao Liu
Chunmiao Liu
HYHang Yu
Hang Yu
BACKGROUND: Pulmonary hypertension (PH) represents a significant cardiovascular disorder marked by both functional and structural alterations within the pulmonary vasculature. Long noncoding RNAs have been closely associated with PH pathogenesis and progression, particularly in vascular remodeling and cell proliferation. Nonetheless, how long noncoding RNAs interact with downstream targets to modulate PH remains unclear. METHODS: The expression levels of LINC00599 were quantified in the mouse lung tissues and pulmonary arterial smooth muscle cells (PASMCs) under hypoxic conditions. The involvement of LINC00599 in PH progression and vascular remodeling was evaluated through in vivo studies. To investigate its role in human PASMC proliferation, small interfering RNA and overexpression plasmids were used. RESULTS: The expression of LINC00599 is upregulated in the medial layer of pulmonary arteries in experimental PH models and hypoxic PASMCs. Administration of lentivirus-mediated shRNA targeting LINC00599 reverses hypoxic PH in murine models. Mechanistically, LINC00599 promotes PASMC proliferation by modulating stress granule formation through m6A (N6-methyladenosine) modification and facilitating liquid-liquid phase separation with MYH9 (myosin heavy chain 9), a process previously implicated in cell-cycle regulation. Furthermore, its expression is driven by a super-enhancer mediated by the transcription factor ZNF263. CONCLUSIONS: This study demonstrates that LINC00599 promotes PH progression by promoting PASMC proliferation via liquid-liquid phase separation—distinct from classical long noncoding RNA mechanisms. The identification of LINC00599 as a modulator of both m6A-dependent stress granule dynamics and MYH9-mediated phase separation expands our understanding of long noncoding RNA functionality in vascular diseases. As a target in a druggable pathway, LINC00599 holds promise for PH precision medicine.

4 February 2025 in European Journal of Pharmacology
Verified
Journal Article
Closed access
JBJune Bai
June Bai
DGDanni Gao
Danni Gao
JMJian Mei
Jian Mei
HYHao Yuan
Hao Yuan
XWXiaoying Wang
Xiaoying Wang
DZDaling Zhu
Daling Zhu

6 December 2025 in European Journal of Pharmacology
Verified
Journal Article
Closed access
SWShanshan Wang
Shanshan Wang
SSShasha Song
Shasha Song
HFHaoxue Feng
Haoxue Feng
HSHanliang Sun
Hanliang Sun
XLXueyin Liao
Xueyin Liao
DZDaling Zhu
Daling Zhu

29 April 2024
Verified
Book Chapter
Open access
PDF file
YWYingqi Wang
Yingqi Wang
DZDaling Zhu
Daling Zhu
HYHang Yu
Hang Yu
Pulmonary arterial hypertension is a disease characterized by complex pathogenesis and high mortality rates following diagnosis. Non-coding RNA plays a pivotal role in the development of pulmonary arterial hypertension, offering promising prospects as a diagnostic and therapeutic target for this condition. The utilization of nucleic acid drugs in disease treatment suggests the feasibility of packaging non-coding RNA into carrier systems and employing them in human pulmonary arterial hypertension (PAH) treatment through appropriate delivery routes. However, currently, no nucleic acid drugs are available for the clinical treatment of PAH. Identifying active regions within non-coding RNA through molecular docking analysis and developing suitable nucleic acid drugs hold great potential for advancing the field of PAH therapeutics.